Completed PHASE2 INTERVENTIONAL 2-arm NCT03858634

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus

Sponsor: Genentech, Inc.

Conditions Chronic Idiopathic Pruritus Chronic Idiopathic Urticaria Lichen Planus Lichen Simplex Chronicus Plaque Psoriasis

Interventions KPL-716 Placebo

Updated 14 times since 2019 Last updated: Mar 4, 2025 Started: May 29, 2019 Primary completion: Apr 1, 2020 Completion: Jun 8, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Idiopathic Pruritus and Chronic Idiopathic Urticaria, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 14 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

14 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Apr 2025 [monthly]

Completed PHASE2
Aug 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2024 — Aug 2024 [monthly]

Completed PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 9 earlier versions

Jan 2021 — Jan 2022 [monthly]

Completed PHASE2
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
May 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2019 — May 2020 [monthly]

Recruiting PHASE2
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE2
Sep 2019 — Nov 2019 [monthly]

Recruiting PHASE2
Aug 2019 — Sep 2019 [monthly]

Recruiting PHASE2
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2019 — Jul 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Kiniksa Pharmaceuticals, Ltd.

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Fort Gratiot, United States , Hot Springs, United States , Johnston, United States , Los Angeles, United States , New Orleans, United States , New York, United States , Normal, United States , Pflugerville, United States , Phoenix, United States and 4 more locations